GlassScriptPhysician profile
Sajeet Sohi
NPI 1689937575
$9,746.39
in general payments reported to CMS, 2019-2025
52 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $1,793 · 2021: $1,987 · 2022: $1,714 · 2023: $743 · 2024: $1,315 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,759 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,758.61 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,703.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,253.39 | 2019-2024 | Trelegy Ellipta, Shingrix, Boostrix |
| Astrazeneca Pharmaceuticals LP | $1,155.61 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $632.77 | 2019-2024 | Amplatzer Talisman, Eterna, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.96 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Pfizer INC. | $453.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $411.51 | 2019-2022 | |
| Abbvie INC. | $380.21 | 2020-2025 | Ubrelvy |
| Astellas Pharma US INC | $358.34 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $249.18 | 2019-2025 | |
| Boston Scientific Corporation | $216.88 | 2020-2025 | Axonics, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $182.36 | 2019-2024 | |
| Lilly USA, LLC | $167.76 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $161.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $155.95 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajeet Sohi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.